Skip to main content
. 2018 Mar 19;2018:1023490. doi: 10.1155/2018/1023490

Figure 4.

Figure 4

Detailed analysis of the impact of idelalisib and ibrutinib on the ADCC of rituximab and obinutuzumab. The differences in the cytotoxicity against CLL cells in cocultures with the NK92-derived effector cells 26.5 (a) or 1708-LC3E11 (b) in the presence and absence of rituximab and obinutuzumab were calculated from the data shown in Figure 3. Means and standard errors of the means are shown. The ADCC of rituximab and obinutuzumab was compared by paired two-tailed t-test. ∗p < 0.05; ∗∗p < 0.01.